While ALK inhibitors have significantly improved the prognosis for patients with ALK-positive NSCLC, their use is associated with a distinct set of adverse events, including serious adverse events (SAEs) that warrant careful attention [66,67,68,69,70,71,72,73,74,75,76]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.